

# INSPIRING BETTER HEALTHCARE SYNDICATED SERVICES

## The Ipsos Global Oncology Monitor

The most comprehensive syndicated database of cancer treatment, with the highest levels of customisation & service.

Geographically representative panels of treating physicians, by appropriate specialty and site of care location, provide:

Physician Demographics			Patient Centric Information			Physician Perceptions		
Specialty	Practice Information	Involvement in clinical trials	Patient Characteristics	Primary Cancer Diagnosis	Stage Currently & at Diagnosis	Patient involvement in drug decision	Dr satisfaction with current regimen	Reasons for selecting current therapy
			Biomarker Testing/ Results	Anti-Cancer Drug Therapy (current & previous)	Supportive Care			

New questions have been added to the monitor to track treatment initiations & switches due to COVID-19, and the number of consultations by telemedicine.

### JUST SOME OF OUR LATEST PUBLICATIONS

#### GATHERING SPEED: THE EVOLUTION OF PROSTATE CANCER TREATMENT

ARTICLE PUBLISHED BY: PharmExec | April 2020

#### GREAT EXPECTATIONS: ARE IMMUNOTHERAPIES THE GATEWAY TO A NEW ERA IN NSCLC TREATMENT?

PAPER PUBLISHED BY: Ipsos | November 2019

#### NEW HORIZONS IN BREAST CANCER TREATMENT: USING PHYSICIAN PERCEPTIONS & BEHAVIOURS TO PREDICT FUTURE TREATMENT PATTERNS

PAPER PUBLISHED BY: Ipsos | October 2019

#### BIOSIMILARS: A DISSIMILAR IMPACT ACROSS SPECIALISMS (NHL vs RA)

PRESENTATION PUBLISHED BY: Ipsos | August 2019

#### IMPACT OF BIOPSY METHODOLOGY ON BIOMARKER TESTING IN NSCLC IN EU5

ONLINE ABSTRACT AT: ASCO 2019 | Chicago | June 2019

#### COMPARATIVE ANALYSIS OF PROFILES OF 65+ YEAR OLD STAGE IV PROSTATE CANCER PATIENTS BY TIME FROM DIAGNOSIS TO FIRST TREATMENT IN THE UNITED STATES

POSTER PRESENTATION AT: ISPOR 2019 | New Orleans, USA

#### TREATMENT APPROACH FOR NONHODGKIN LYMPHOMA PATIENTS SINCE FIRST BIOSIMILARS OF RITUXIMAB APPROVED IN EU5

ORAL PRESENTATION AT: ASCO 2019 | Chicago | June 2019



# The Key Facts about **Global Therapy Monitors**

## GLOBAL COVERAGE

### Countries Capturing All Drug Treated Tumour Types\*

USA	ITALY	INDIA
UK	SPAIN	KOREA
FRANCE	CHINA	JAPAN
GERMANY	AUSTRALIA	

*\* all tumours covers both solid tumours and haematologic malignancies*

### Tumour Specific Countries

RUSSIA	PHILIPPINES	SAUDI ARABIA
SWITZERLAND	INDONESIA	UAE
AUSTRIA	SINGAPORE	QATAR
BELGIUM	VIETNAM	MEXICO
NETHERLANDS	THAILAND	BRAZIL
GREECE	EGYPT	ARGENTINA
POLAND	BAHRAIN	COLOMBIA
PORTUGAL	OMAN	ALGERIA
TAIWAN	KUWAIT	LEBANON

## REPORTING FREQUENCY

US	Monthly
EU(5)	Monthly
JAPAN	Quarterly
CHINA	Bi-Annually (option for quarterly)
AUSTRALIA	Quarterly
KOREA	Quarterly
INDIA	Bi-Annually

## ADVANTAGES

- Treatment patterns and outcomes for a statistically robust sample of patients**
- Greatest breadth and depth of drug-treated patients**
- Globally comparable and historical trended data available**
- Regional representation in each country and inclusion of all practice types, e.g. academic hospitals and accredited centres**
- Unrivalled flexibility of patient and physician data provide scientifically rigorous and rapid answers to a variety of business questions**
- Highest level of service by senior team of Oncology experts**

### About the Ipsos Healthcare Service Line

Ipsos partners with pharmaceutical, bio-tech and medical device manufacturers to inspire better healthcare. Operating in over 50 countries, our 1000+ experts support key business decisions for our clients throughout the commercial lifecycle, from early-stage strategy, to launch, to performance optimisation. We do this through a uniquely integrated combination of therapeutic and market expertise, gold standard real world evidence, and market-leading custom research approaches – all underpinned by a global footprint and unprecedented access to today's healthcare stakeholders.